4:30 pm Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan; The study met its primary efficacy endpoint – HedgeChatter

4:30 pm Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan; The study met its primary efficacy endpoint

03 Apr

4:30 pm Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan; The study met its primary efficacy endpoint

Bystocknews GILD, stock Comments Off

View todays social media effects on GILD

View the latest stocks trending across Twitter. Click to view dashboard

See who Gilead is hiring next, click here to view

Author